A B S T R A C T The effect of sequential methotrexate and 5-fluorouracil on the clonal growth of the human colon adenocarcinoma cell, HCT-8, and the hormonedependent human breast carcinoma cell, 47-DN, was examined. In both cell lines, when 5-fluorouracil was given during the last 6 h of a 24-h methotrexate exposure period, there was marked synergistic inhibition of clonal growth. Shorter intervals or the reverse sequence of drugs were either additive or antagonistic. These results indicate the importance of the drug sequence and time interval between drug administration for optimal cytotoxicity in these human cell lines. This information suggests that the administration of of methotrexate 18 h before 5-fluorouracil may have potential application in the design of clinical trials for these malignancies.
INTRODUCTION
Methotrexate (MTX)1 and 5-fluorouracil (FUra) have been used successfully singly, and in combination, in treating a variety of human neoplasms, including cancers of the breast and colon (1, 2) . Biochemical investigations have elucidated the specific molecular mechanisms by which each of these drugs exerts its cytotoxic effect, but there remains some controversy about the optimum therapeutic effectiveness when these two antimetabolites are combined (3) . Previous work from our laboratory has demonstrated that pretreating cultured murine leukemic cells with MTX results in enhanced intracellular accumulation of FUra and synergistic tumor-cell kill (4) . To extend our studies to human tumor cells we have adopted the simple technique of monolayer cloning. Although human tumor-cell lines and suspensions from freshly resected tumor specimens can be cloned in soft agar, this technique is tedious and the cloning efficiency is often very sensitive to specific growth factors (5 clonal growth of HCT-8 cells. 0.1 ,M MTX for 24 h resulted in 40% clonal growth. The effect of combining MTX and FUra was found to be schedule dependent. FUra given during the first 6 h of the 24-h MTX exposure did not inhibit clonal growth more than when MTX alone was given. As the 6-h FUra dose was given progressively later into the 24-h MTX-exposure period, synergistic inhibition of clonal growth was observed. 6 h of 10 MM FUra reduced 47-DN clonal growth to 25%, and 24 h of 0.1
MuM MTX resulted in 67% clonal growth (Fig. 3) . FUra
given during the first 6 h of a 24-h MTX-treatment period resulted in no greater growth inhibition than was seen with FUra alone. If the inhibitory effects of MTX and FUra were entirely independent, the com- bined addition would have been additive, and closer to 17% of control. Only when the 6-h FUra dose was given later into the 24-h MTX-treatment period did the combined inhibitory effect of these two drugs become synergistic.
DISCUSSION
Our data suggest that a relatively simple monolayer colony-forming assay can be used to assess the cytotoxicity of sequence-dependent combination drug therapy in vitro against human malignant cell lines. In the human colorectal adenocarcinoma, HCT-8, and the hormone-dependent breast carcinoma, 47-DN, combining MTX and FUra resulted in inhibition of clonal growth which ranged from less than additive to synergistic, depending on the sequencing interval. MTX pretreatment for [12] [13] [14] [15] [16] [17] [18] h before FUra therapy was needed to produce synergistic growth inhibition in both human cell lines.
Combining MTX and FUra can alter the growthinhibitory mechanisms of both drugs in a complex fashion. MTX reduces formation of thymidylate and subsequently inhibits nucleic acid and protein synthesis (1). These effects result from the binding of MTX to dihydrofolate reductase (E.C.1.5.1.3.) and the subsequent depletion of intracellular pools of methylenetetrahydrofolate (CH2FAH4). FUra is thought to inhibit cell growth after the intracellular conversion to fluorodeoxyuridylate (FdUMP) which binds in a covalent ternary complex with CH2FAH4 and the enzyme thymidylate synthetase (E.C.2.7.4.6.) to inhibit DNA synthesis (2) . FUra toxicity has also been correlated with the intracellular formation of fluorouridine triphosphate and its incorporation into RNA (8 of CH2FAH4, pretreating cells with FUra could antagonize the cytotoxicity of MTX. In vitro studies of the interaction between MTX and the ternary complex formed in FUra-treated cells suggest that the drug combination of MTX and FUra is antagonistic regardless of the sequence in which they are given (9 
